RxDoctor Payments Data

Vinay Kumar, MD

Internal Medicine · Marlborough, MANPI 1164489118

Payments from drug & device makers

$536in general payments, 2019–2025

Across 26 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$273
  • AstraZeneca$99
  • GSK$78
  • Novartis$38
  • Abbott$25
  • Novo Nordisk$16
  • plus $8 from 1 others

What the payments were for

  • Food & beverage$536100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer13$273
AstraZeneca4$99
GSK4$78
Novartis2$38
Abbott1$25
Novo Nordisk1$16
Inogen, Inc.1$8

How this compares

$536 in reported general payments places this provider in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$234,608
Medicare patients
300
Services billed
3,482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban122$116,176
JardianceEmpagliflozin40$53,448
OzempicSemaglutide31$48,922
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$31,831
XareltoRivaroxaban18$26,979
OxycontinOxycodone Hcl29$25,001
Atorvastatin Calcium330$6,064
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl54$5,173
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$4,739
Metoprolol Succinate169$3,494
Irbesartan61$3,276
Desvenlafaxine Succinate ErDesvenlafaxine Succinate37$3,258
Omeprazole188$3,105
Levothyroxine Sodium184$2,847
Albuterol Sulfate HfaAlbuterol Sulfate53$2,357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$273$116,176122 claims
Novo NordiskOzempic$16$48,92231 claims
GSKTrelegy Ellipta$78$31,83144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Marlborough

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →